Keywords: Yttrium radioisotopes, Liver neoplasms, Embolization, Therapeutic synergism, Carcinoma, Transitional cell, Immunotherapy, Case report Primary transitional cell carcinoma of the ureter is a rare type of cancer with an estimated annual incidence of 1.8 cases per 100,000 person-years in the USA. It is a very aggressive disease with metastasis presented in approximately 25% at diagnosis with a median overall survival of 21 months for advanced-stage patients [1, 2].
